
Roche
Research containing Roche
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Roche in 1 CB Insights research brief, most recently on Oct 28, 2022.
Expert Collections containing Roche
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Roche is included in 1 Expert Collection, including Conference Exhibitors.
Conference Exhibitors
5,302 items
Roche Patents
Roche has filed 790 patents.
The 3 most popular patent topics include:
- Molecular biology
- Biotechnology
- Analytical chemistry

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
5/27/2021 | 9/19/2023 | Analytical chemistry, Chromatography, Blood tests, Fluid dynamics, Molecular biology | Grant |
Application Date | 5/27/2021 |
---|---|
Grant Date | 9/19/2023 |
Title | |
Related Topics | Analytical chemistry, Chromatography, Blood tests, Fluid dynamics, Molecular biology |
Status | Grant |
Latest Roche News
Sep 13, 2023
Signal: Roche to refile subcutaneous Tecentriq with FDA after UK approval Roche planned to launch the new formulation this year, but it will be pushed back after tweaks requested by FDA. Roche has pushed back the launch of its subcutaneous Tecentriq to 2024. Pharmaceuticals giant Roche reportedly plans to file a new application for subcutaneous oncology drug Tecentriq with the FDA by the end of the year. Recommended Reports Tecentriq is already Roche’s second best-selling oncology drug, and the subcutaneous version has the advantage of being significantly easier to administer, taking a mere seven minutes to the minimum half hour that the current intravenous formulation requires. An FDA approval of the new formula would likely increase sales in the US, boosting the already impressive $2.1bn global revenue in H1 2023. The drug was initially meant to launch in 2023, but Roche had to update its chemistry, manufacturing and controls activities in line with FDA regulations, slowing the process. A representative for the company told Endpoints that the delay was purely process-based, and has no impact on patient safety. Given that the UK has strict drug approval rules, it seems likely that the tweaked drug will be successful in the US as well. Roche has partnered with Halozyme Therapeutics to produce the subcutaneous version, the second time it has done this after Ocrevus, a multiple sclerosis drug. Their novel Enhanze drug-delivery system allows for more stable subcutaneous delivery. The FDA approval of that drug earlier this year further suggests that the drug will see success. Halozyme’s partnership cost Roche $190m in 2017, at the same time as Halozyme was also inking deals with Roche’s competitors, including Bristol-Myers Squibb, whiic is working on a subcutaneous form of its own oncology drug Opdivo. Our signals coverage is powered by GlobalData’s Thematic Engine , which tags millions of data items across six alternative datasets — patents, jobs, deals, company filings, social media mentions and news — to themes, sectors and companies. These signals enhance our predictive capabilities, helping us to identify the most disruptive threats across each of the sectors we cover and the companies best placed to succeed. Share this article
Roche Frequently Asked Questions (FAQ)
Where is Roche's headquarters?
Roche's headquarters is located at Medicinalvarer OG, Hvidovre.
Who are Roche's competitors?
Competitors of Roche include MedicSen.
Compare Roche to Competitors

Portal Instruments is developing a unique platform technology to transform the delivery of modern medicines and improve the patient experience. The company's technology enables the precise delivery of the exact amount of drug at the desired tissue depth irrespective of drug viscosity and composition. Its delivery mechanism is painless to the patient and silent. It is also highly customizable across a large variety of medical, animal, agricultural, and cosmetic applications. The company was founded in 2012 and is based in Cambridge, Massachusetts.
Subcuject develops a wearable, medical device that allows for self-administration of larger doses of drugs. It is based in Hellebaek, Denmark.

Medicsen delivers a diabetes management application combining smart patch administration, glucose sensors, and artificial intelligence. It develops a needle-free smart patch for the painless delivery of large drugs like insulin, heparin, or antibodies using safe ultrasound waves. It was founded in 2015 and is based in Madrid, Spain.

Insulet manufactures medical devices for people with diabetes. Its product Omnipod is a wearable disposable pod that provides up to three days of insulin delivery, without the need to see or handle a needle. It was founded in 2000 and is based in Acton, Massachusetts.

Tandem Diabetes Care (NASDAQ: TNDM) is a medical device manufacturing company. It designs and develops diabetic care products. It offers t:slim X2 insulin pump, a tubeless insulin pump that delivers insulin in precise doses throughout the day and night. It was founded in 2006 and is based in San Diego, California.